Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount
Another In Works From Hetero
Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy.
You may also be interested in...
India’s Zydus Cadila is working on strengthening its pipeline with 35 product approvals from the FDA over the course of its most recent financial year. The company also filed for 22 new ANDAs during FY2021. And ahead of recently launching the world’s first biosimilar to Roche’s Kadcyla (trastuzumab emtansine) in India, the company reported significant growth in its domestic business.
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
After only two weeks of the first-quarter 2020 earnings season for biopharmaceutical companies, the tempo of the announcements seems already to have been defined. Unless companies are exposed to, on the one hand, medical devices, or on the other, consumer health or diagnostics, the impact of the coronavirus pandemic on pure play biopharmaceutical companies has so far been marginal.